telmisartan has been researched along with Diabetic Glomerulosclerosis in 76 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (44.74) | 29.6817 |
| 2010's | 37 (48.68) | 24.3611 |
| 2020's | 5 (6.58) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, W; Lei, C; Wei, L; Zhan, X | 1 |
| Abdel Hamid, AM; Abdel Monsef, AS; Abdo, W; Ahmeda, AF; Amer, ME; Antar, SA; El-Moselhy, LE; Farage, AE; Kamel, EM; Mahmoud, AM; Taha, RS | 1 |
| Gaikwad, AB; Kale, A; Sankrityayan, H; Shelke, V | 1 |
| Escalada, FJ; Fernández-Seara, MA; Garcia-Fernandez, N; Mora-Gutiérrez, JM; Orbe, J; Páramo, JA; Riera, M; Rodríguez, JA; Slon Roblero, MF; Soler, MJ | 1 |
| Gill, A; Jarolimek, W; Pollock, C; Saad, S; Schilter, H; Stangenberg, S; Wong, MG; Wong, MY; Zaky, A | 1 |
| Ahad, A; Ahmad, A; Al-Jenoobi, FI; Al-Mohizea, AM; Raish, M | 1 |
| Gill, A; Pollock, CA; Saad, S; Schilter, HC; Stangenberg, S; Wong, MG; Zaky, A | 1 |
| Chernatska, O; Demikhova, N | 1 |
| Bao, L; Gao, P; Wu, X; Yao, T; Zha, D | 1 |
| Gaikwad, AB; Malek, V; Sankrityayan, H; Sharma, N | 1 |
| Asanuma, K; Fukami, K; Kaida, Y; Kaifu, K; Matsui, T; Okuda, S; Takeuchi, M; Ueda, S; Yamagishi, S | 1 |
| Gangadharan Komala, M; Gross, S; Huang, C; Mather, A; Mudaliar, H; Panchapakesan, U; Pegg, K; Pollock, CA; Shen, S | 1 |
| Chen, H; Li, BY; Peng, H; Xiong, DL; Yi, J | 1 |
| Cai, G; Chen, X; Guan, X; Li, J; Li, W; Liu, M; Liu, W; Liu, Y; Lun, L; Wang, Y; Wu, H; Yao, H; Yin, S; Zhang, J; Zheng, Y; Zhou, C; Zhu, H; Zhuang, X | 1 |
| Albayrak, B; Bilen, Y; Cankaya, E; Cerrah, S; Cetinkaya, R | 1 |
| El-Kadem, AH; El-Mahdy, NA; El-Sayad, ME | 1 |
| Gaikwad, AB; Goru, SK; Kadakol, A; Malek, V; Pandey, A; Sharma, N | 1 |
| Deng, A; Liu, J; Wang, J; Yao, L; Zhao, H | 1 |
| Galle, J | 1 |
| Babazono, T; Haneda, M; Ito, S; Iwamoto, Y; Katayama, S; Kawamori, R; Makino, H; Moriya, T; Takeuchi, M | 2 |
| Hosomi, N; Imanishi, M; Ito, S; Kiyomoto, H; Kobori, H; Konishi, Y; Meda, I; Mori, T; Morikawa, T; Nagai, Y; Nakagawa, T; Nishiyama, A; Okada, N; Okumura, M | 1 |
| Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y | 1 |
| Chan, CM; Wong, KS; Woo, KT | 1 |
| Bichu, P; Khan, A; Nistala, R; Sowers, JR; Whaley-Connell, A | 1 |
| Avezum, A; Cardona-Munoz, E; Dagenais, GR; Diaz, R; Dyal, L; Fodor, G; Maillon, JM; Mann, JF; McQueen, MJ; Pogue, J; Probstfield, JL; Rydén, L; Schmieder, RE; Schumacher, H; Teo, KK; Wang, X; Yu, CM; Yusuf, S | 1 |
| Chaisuvannarat, V; Krairittichai, U | 1 |
| Mazerska, M; Myśliwiec, M | 1 |
| Azuma, K; Dejima, T; Kanaoka, T; Maeda, A; Masuda, S; Ohsawa, M; Tamura, K; Umemura, S; Wakui, H; Yanagi, M | 1 |
| Heinig, M; Kosugi, T; Matsuo, S; Nakagawa, T; Nakayama, T | 1 |
| Kashihara, N; Kobayashi, S; Kuwabara, A; Sasaki, T; Satoh, M; Tomita, N | 1 |
| Gaikwad, AB; Mulay, SR; Tikoo, K | 1 |
| de Boer, IH; Pichler, RH | 1 |
| Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y | 1 |
| Anantharaman, R; Bhadada, SK; Bhansali, A; Dutta, P; Jayaprakash, P; Kohli, HS; Upreti, V; Walia, R | 1 |
| Pollock, CA; Ritz, E; Schmieder, RE | 1 |
| Aizawa, Y; Giridharan, VV; Harima, M; Kodama, M; Lakshmanan, AP; Sari, FR; Soetikno, V; Thandavarayan, RA; Watanabe, K | 1 |
| Jain, A; Rao, RP; Srinivasan, B | 1 |
| Makino, H; Ogawa, D | 1 |
| Fujishima, H; Fujita, H; Komatsu, K; Morii, T; Narita, T; Sakamoto, T; Takahashi, T; Yamada, Y | 1 |
| Cao, Z; Cooper, ME | 1 |
| Anabitarte-Prieto, A; Companioni, O; García-Bello, MA; Nóvoa-Mogollón, FJ; Plaza-Toledano, C; Rodríguez-Esparragón, F; Rodríguez-Pérez, JC; Suárez-Ortega, S | 1 |
| Fujishima, H; Fujita, H; Hosoba, M; Komatsu, K; Morii, T; Narita, T; Sakamoto, T; Takahashi, K; Takahashi, T; Yamada, Y | 1 |
| Anantharaman, R; Bhadada, SK; Bhansali, A; Jayaprakash, P; Kohli, HS; Shanmugasundar, G; Walia, R | 1 |
| Fujimoto, M; He, P; Honjo, S; Ishibashi, R; Ishikawa, T; Koshizaka, M; Mezawa, M; Okabe, E; Onishi, S; Saito, Y; Sato, S; Takemoto, M; Tokuyama, H; Tsurutani, Y; Ueda, S; Yokote, K | 1 |
| Balakumar, P; Bishnoi, HK; Mahadevan, N | 2 |
| Abe, M; Fujii, Y; Ito, M; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y | 1 |
| Tawfik, MK | 1 |
| Alter, ML; Henze, A; Hocher, B; Krause-Relle, K; Kretschmer, A; Ott, IM; Raila, J; Sharkovska, Y; Stasch, JP; Tsuprykov, O; von Websky, K | 1 |
| Alter, ML; Henze, A; Hocher, B; Klein, T; Krause-Relle, K; Ott, IM; Raila, J; Sharkovska, Y; Tsuprykov, O; von Websky, K | 1 |
| Eguchi, J; Kodera, R; Makino, H; Nakatsuka, A; Ogawa, D; Sato-Horiguchi, C; Shikata, K; Tachibana, H; Terami, N; Wada, J | 1 |
| Dhakad, PK; Joshi, M; Joshi, S; Kanawat, DS; Kurmi, MK; Mishra, A; Raikwar, SK; Sharma, AK; Sharma, P; Srinivasan, BP; Srivastava, V | 1 |
| Bain, SC; Barnett, AH; Bouter, P; Jervell, J; Karlberg, B; Madsbad, S; Mustonen, J | 1 |
| Konecný, K; Kosatíková, Z; Metelka, R; Vymetal, J; Weinbergová, O | 1 |
| Zidek, W | 1 |
| Asgari, AA; Sarvghadi, F; Zahed, N | 1 |
| Loewenstein, JE | 1 |
| Hovind, P; Parving, HH; Rossing, P | 1 |
| Dahlöf, B; Ritz, E | 1 |
| Barnett, AH | 1 |
| Luño, J | 1 |
| Altuntas, Y; Aydin, L; Kürklü, A; Sengul, AM | 1 |
| Baliga, V; Desai, A; Gawde, A; Hariharan, RS; Kulkarni, BN; Kulkarni, RB; Naikwadi, A | 1 |
| Böger, RH; Maas, R; Quispe-Bravo, S; Schwedhelm, E; Skamira, C | 1 |
| Barnett, A | 2 |
| He, XL; Li, JP; Li, Q | 1 |
| Koide, H; Nakamura, T; Sugaya, T | 1 |
| Chachin, M; Hayashi, N; Hayashi, T; Horie, Y; Konomi, A; Matsumaru, T; Ohmura, T; Seidler, R; Sumida, T; Tsunenari, I | 2 |
| Deng, AG; Liu, JS; Wang, JQ; Yao, LJ | 1 |
| Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C | 1 |
| Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M | 1 |
9 review(s) available for telmisartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Reduction of proteinuria with angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Hemodynamics; Humans; Losartan; Mineralocorticoid Receptor Antagonists; PPAR gamma; Proteinuria; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan; Treatment Outcome | 2009 |
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Benzimidazoles; Benzoates; Diabetic Nephropathies; Humans; Hyperkalemia; Models, Biological; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan | 2010 |
Renal protection in diabetes: lessons from ONTARGET.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetic Nephropathies; Humans; Hypertension, Renal; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan | 2010 |
Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Renin-Angiotensin System; Risk Factors; Telmisartan | 2012 |
Telmisartan in the management of diabetic nephropathy: a contemporary view.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetes Mellitus; Diabetic Nephropathies; Disease Progression; Female; Humans; Hypertension; Kidney Diseases; Male; Telmisartan; Treatment Outcome | 2012 |
Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Female; Glomerular Filtration Rate; Humans; Hypertension; Longitudinal Studies; Male; Randomized Controlled Trials as Topic; Telmisartan | 2005 |
[Renin-angiotensin system in diabetic nephropathy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Homeostasis; Humans; Lisinopril; Losartan; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Telmisartan | 2005 |
Prevention of loss of renal function over time in patients with diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Agents; Diabetic Nephropathies; Enalapril; Glomerular Filtration Rate; Humans; Kidney; Kidney Failure, Chronic; Proteinuria; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan; Time Factors; Treatment Outcome | 2006 |
23 trial(s) available for telmisartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
IMPROVEMENT OF TREATMENT IN PERSONS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Glycated Hemoglobin; Humans; Hypertension; Lisinopril; Middle Aged; Renin-Angiotensin System; Telmisartan; Treatment Outcome | 2018 |
[Efficacy observation of treating diabetic nephropathy by shenshuaining granule combined telmisartan tablet].
Topics: Adult; Albumins; Antihypertensive Agents; Benzimidazoles; Benzoates; Diabetic Nephropathies; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Phytotherapy; Tablets; Telmisartan | 2015 |
Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Benzimidazoles; Benzoates; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperkalemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Probucol; Proteinuria; Telmisartan; Treatment Outcome | 2016 |
Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATI
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Humans; Hypertension, Renal; Japan; Male; Middle Aged; Telmisartan; Treatment Outcome | 2008 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Effect of telmisartan on renal outcomes: a randomized trial.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Coronary Artery Disease; Creatinine; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Risk Factors; Telmisartan | 2009 |
Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Topics: Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Synergism; Drug Therapy, Combination; Enalapril; Female; Humans; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Telmisartan; Treatment Outcome | 2009 |
Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
Topics: Aged; Albuminuria; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Telmisartan | 2009 |
Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Ankle Brachial Index; Benzimidazoles; Benzoates; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Prospective Studies; Proteinuria; Regression Analysis; Telmisartan; Young Adult | 2009 |
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acid-Binding Proteins; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Treatment Outcome | 2010 |
[INNOVATION study].
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Telmisartan | 2010 |
Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antioxidants; Benzimidazoles; Benzoates; Cross-Over Studies; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Japan; Losartan; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Superoxide Dismutase; Telmisartan; Tyrosine | 2011 |
Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Creatinine; Diabetic Nephropathies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Male; Middle Aged; Prospective Studies; Sulfonamides; Telmisartan; Torsemide; Treatment Outcome | 2011 |
Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Albuminuria; Aldosterone; Amides; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fatty Acid-Binding Proteins; Female; Fumarates; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Renin; Telmisartan; Young Adult | 2012 |
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enalapril; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Prospective Studies; Telmisartan | 2004 |
Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Diabetic Nephropathies; Female; Heart Rate; Humans; Hypertension, Renal; Kidney Failure, Chronic; Male; Telmisartan | 2004 |
Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Creatinine; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Hypertension; Lisinopril; Male; Middle Aged; Prospective Studies; Telmisartan | 2006 |
A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Infant; Male; Middle Aged; Pilot Projects; Prospective Studies; Safety; Single-Blind Method; Telmisartan | 2005 |
Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enalapril; Glomerular Filtration Rate; Humans; Kidney Diseases; Kidney Failure, Chronic; Receptors, Angiotensin; Renin-Angiotensin System; Telmisartan | 2006 |
[Clinical study on treatment of early diabetic nephropathy by tangshenling combined with telmisartan].
Topics: Adult; Aged; Benzimidazoles; Benzoates; Diabetic Nephropathies; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Phytotherapy; Telmisartan | 2006 |
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetic Nephropathies; Double-Blind Method; Humans; Middle Aged; Placebos; Telmisartan | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Creatinine; Diabetic Nephropathies; Double-Blind Method; Female; Half-Life; Humans; Hypertension; Losartan; Male; Middle Aged; Proteinuria; Telmisartan | 2008 |
44 other study(ies) available for telmisartan and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Telmisartan Mitigates High-Glucose-Induced Injury in Renal Glomerular Endothelial Cells (rGECs) and Albuminuria in Diabetes Mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Membrane Permeability; Diabetic Nephropathies; Endothelial Cells; Humans; Kidney Glomerulus; Male; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Mitochondria; Occludin; Oxidative Stress; Receptor, Angiotensin, Type 1; Telmisartan | 2021 |
Telmisartan attenuates diabetic nephropathy by mitigating oxidative stress and inflammation, and upregulating Nrf2/HO-1 signaling in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Heme Oxygenase (Decyclizing); Inflammation; Kidney; Male; Molecular Docking Simulation; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley; Signal Transduction; Streptozocin; Telmisartan | 2022 |
Evaluating the potential of tauroursodeoxycholic acid as add-on therapy in amelioration of streptozotocin-induced diabetic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus; Diabetic Nephropathies; Rats; Rats, Wistar; Streptozocin; Taurochenodeoxycholic Acid; Telmisartan | 2023 |
MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Male; Matrix Metalloproteinase 10; Mice; Mice, Inbred C57BL; Middle Aged; Prognosis; Renin-Angiotensin System; Telmisartan | 2020 |
Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy.
Topics: Albuminuria; Allylamine; Amine Oxidase (Copper-Containing); Animals; Benzamides; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Fibronectins; Fibrosis; Kidney Glomerulus; Kidney Tubules; Leukocyte Common Antigens; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Renal Insufficiency, Chronic; Telmisartan | 2020 |
Development and biological evaluation of vesicles containing bile salt of telmisartan for the treatment of diabetic nephropathy.
Topics: Animals; Antioxidants; Bile Acids and Salts; Biomarkers; Diabetic Nephropathies; Drug Compounding; Oxidative Stress; Rats; Telmisartan | 2018 |
Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy.
Topics: Albuminuria; Amino Acid Oxidoreductases; Animals; Collagen; Diabetic Nephropathies; Enzyme Inhibitors; Fibronectins; Kidney; Male; Mice; Mice, Inbred C57BL; Telmisartan | 2018 |
Telmisartan attenuates diabetic nephropathy progression by inhibiting the dimerization of angiotensin type-1 receptor and adiponectin receptor-1.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dimerization; Disease Models, Animal; Fibrosis; Kidney; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adiponectin; RNA, Small Interfering; Streptozocin; Telmisartan | 2019 |
Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diminazene; Fibrosis; Inflammation; Kidney; Male; Neprilysin; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Renin-Angiotensin System; Streptozocin; Telmisartan; Thiorphan | 2019 |
Telmisartan inhibits AGE-induced podocyte damage and detachment.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blotting, Western; Cell Adhesion; Diabetic Nephropathies; Disease Models, Animal; DNA Damage; Glycation End Products, Advanced; L-Lactate Dehydrogenase; Mice; Podocytes; Telmisartan | 2013 |
Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Benzimidazoles; Benzoates; Blood Glucose; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; Glucose Transporter Type 1; Glucosides; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Telmisartan; Toll-Like Receptor 2; Transforming Growth Factor beta1 | 2014 |
The effects of dual and triple combinations of trandolapril, telmisartan, and verapamil on overt proteinuria in the patients with diabetic nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Indoles; Male; Middle Aged; Proteinuria; Telmisartan; Verapamil; Young Adult | 2016 |
Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cholesterol, LDL; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Glycation End Products, Advanced; Interleukin-1beta; Kidney; Nitric Oxide; Proteinuria; Rats; Sildenafil Citrate; Streptozocin; Superoxide Dismutase; Telmisartan; Transforming Growth Factor beta1 | 2016 |
H2AK119 monoubiquitination regulates Angiotensin II receptor mediated macrophage infiltration and renal fibrosis in type 2 diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blotting, Western; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Histones; Imidazoles; Kidney; Lysine; Macrophages; Male; Promoter Regions, Genetic; Pyridines; Rats, Wistar; Receptors, Angiotensin; Reverse Transcriptase Polymerase Chain Reaction; Telmisartan; Transforming Growth Factor beta1; Ubiquitination | 2016 |
Effect of Micardis on the expression of renal medulla aquaporin-2 in diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporin 2; Benzimidazoles; Benzoates; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Immunohistochemistry; Kidney; Kidney Medulla; Male; Mice; Mice, Inbred C57BL; Telmisartan | 2008 |
Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Collagen; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypertension, Renal; Kidney Cortex; Male; Podocytes; Rats; Rats, Inbred OLETF; RNA, Messenger; Telmisartan | 2008 |
Telmisartan is more effective than losartan in reducing proteinuria.
Topics: Benzimidazoles; Benzoates; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Losartan; Proteinuria; Telmisartan; Treatment Outcome | 2009 |
Telmisartan did not prevent renal disease in patients without proteinuria.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Coronary Artery Disease; Creatinine; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Risk Factors; Telmisartan | 2009 |
eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Delivery Systems; Enalapril; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Nitric Oxide Synthase Type III; Renin-Angiotensin System; Streptozocin; Telmisartan; Treatment Failure | 2010 |
In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Benzoates; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerular Filtration Rate; Kidney Glomerulus; Male; Microcirculation; Microscopy, Fluorescence, Multiphoton; Rats; Rats, Sprague-Dawley; Renal Circulation; Telmisartan | 2010 |
Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimidazoles; Benzoates; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation; Inflammation; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Streptozocin; Telmisartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2010 |
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.
Topics: Albumins; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Drug Combinations; Female; Humans; Male; Potassium; Ramipril; Statistics, Nonparametric; Telmisartan | 2010 |
Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Benzoates; Collagen Type III; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Hypertrophy; Intracellular Signaling Peptides and Proteins; Kidney; Mice; NADPH Oxidases; Oxidative Stress; Peptidyl-Dipeptidase A; PPAR gamma; Protein Serine-Threonine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, G-Protein-Coupled; Superoxides; Telmisartan; Transforming Growth Factor beta1; Up-Regulation | 2011 |
Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Fasting; Female; Fibronectins; Indoles; Male; Rats; Telmisartan; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2011 |
Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.
Topics: Acetophenones; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Chemical Analysis; Blood Glucose; Blotting, Western; Diabetes Mellitus; Diabetic Nephropathies; Dinoprostone; Enzyme Inhibitors; Hyperglycemia; Immunohistochemistry; Kidney; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; NF-E2-Related Factor 2; Superoxide Dismutase; Superoxides; Telmisartan | 2012 |
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Ramipril; Telmisartan | 2011 |
An angiotensin II type 1 receptor blocker prevents renal injury via inhibition of the Notch pathway in Ins2 Akita diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Calcium-Binding Proteins; Cells, Cultured; Diabetes Mellitus; Diabetic Nephropathies; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Kidney Glomerulus; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Receptor, Notch1; Serrate-Jagged Proteins; Signal Transduction; Telmisartan; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2012 |
Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glutathione; Hypoglycemic Agents; Inflammation Mediators; Kidney; Lipid Peroxidation; Lipid Peroxides; Oxidative Stress; Pioglitazone; Rats; Reperfusion Injury; Superoxide Dismutase; Telmisartan; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha | 2012 |
The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Creatine; Diabetes Mellitus; Diabetic Nephropathies; Drug Therapy, Combination; Female; Fenofibrate; Hypolipidemic Agents; Kidney; Lipids; Male; Nitrogen; Oxidative Stress; PPAR alpha; Proteinuria; Rats; Rats, Wistar; Streptozocin; Telmisartan | 2012 |
Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Blood Glucose; Blood Pressure; Diabetic Nephropathies; Disease Models, Animal; Guanylate Cyclase; Kidney Function Tests; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Organ Size; Pyrazoles; Pyrimidines; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Telmisartan | 2012 |
DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Linagliptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Oxidative Stress; Purines; Quinazolines; Streptozocin; Telmisartan; Treatment Outcome | 2012 |
Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice.
Topics: Animals; Benzimidazoles; Benzoates; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Inflammation Mediators; Male; Mice; Mice, Congenic; Mice, Inbred Strains; Oxidative Stress; Reactive Oxygen Species; Telmisartan | 2012 |
Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Topics: Adamantane; Albuminuria; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Drug Therapy, Combination; Fasting; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Rats, Wistar; Systole; Telmisartan; Vildagliptin | 2014 |
[Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Long-Term Care; Renal Dialysis; Telmisartan; Treatment Outcome | 2004 |
Telmisartan vs. enalapril in type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Diabetic Nephropathies; Enalapril; Humans; Hyperlipidemias; Risk Factors; Telmisartan | 2005 |
Telmisartan vs. enalapril in type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetic Nephropathies; Enalapril; Fees, Pharmaceutical; Glomerular Filtration Rate; Humans; Telmisartan | 2005 |
Telmisartan vs. enalapril in type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Glomerular Filtration Rate; Humans; Telmisartan; Therapeutic Equivalency | 2005 |
Introduction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Hypoglycemic Agents; Obesity; Telmisartan | 2005 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Benzimidazoles; Benzoates; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Endothelium, Vascular; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Renal Insufficiency; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
[In the DETAIL. Kidney protection in manifestations of microalbuminuria].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Enalapril; Glomerular Filtration Rate; Humans; Kidney; Prospective Studies; Randomized Controlled Trials as Topic; Telmisartan; Time Factors | 2006 |
Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Creatinine; Diabetic Nephropathies; Fatty Acid-Binding Proteins; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan | 2007 |
Renoprotective effects of telmisartan in the 5/6 nephrectomised rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Diabetic Nephropathies; Disease Models, Animal; Enalapril; Kidney; Nephrectomy; Rats; Telmisartan | 2007 |
[Protein kinase C-betaI, betaII in mouse diabetic nephropathy kidney and its relation to nephroprotective actions of the angiotensin receptor blocker telmisartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Diabetic Nephropathies; Fluorescent Antibody Technique; Isoenzymes; Kidney; Male; Mice; Mice, Inbred C57BL; Protein Kinase C; Telmisartan; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2007 |
Renoprotective effects of telmisartan on renal injury in obese Zucker rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney; Male; Proteinuria; Rats; Rats, Zucker; Telmisartan; Triglycerides; Urine | 2012 |